Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative tenofovir vs no antiviral therapy in HBV-DNA–negative HBV-related HCC after hepatectomy
ChiCTR2200058194Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tenofovir disoproxil fumarate in hepatocellular carcinoma (HCC) and Chronic Hepatitis B (CHB) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: recurrence-free survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatocellular carcinoma (HCC)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200058194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058194.